More than 44 million people worldwide are affected by Alzheimer’s disease. Patients suffer from memory loss, progressive impairments in speech and written language, as well as in performing daily activities. According to statistics, one in three people die from Alzheimer’s or another dementia-related disorder, making it the sixth most fatal disease in the US alone. Babu™ is proud to announce that it has partnered with US company Telocyte preparing to begin clinical trials for the first telomerase-based gene therapy treating the actual cause of Alzheimer’s disease, not just its symptoms. But that’s not all: Telocyte is not just a cure for Alzheimer’s – it is a treatment platform for at least a dozen ageing diseases present in more than 1/7 of the human population.